SCHEMBL30474113

SCHEMBL30474113

CC(C)(C)OC(=O)N1CCc2cc(I)c(OCc3ccc(Cl)cc3)nc2C1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ESR2 Q92731 1/20 0.47
NR1H2 P55055 1/20 0.42
MAPK1 P28482 2/20 0.42
MKNK1 Q9BUB5 2/20 0.39
MAPT P10636 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
STS P08842 1/20 0.38
GPR119 Q8TDV5 5/20 0.38
LMNA P02545 1/20 0.37
TP53 P04637 1/20 0.37
VEGFA P15692 1/20 0.37
EGLN1 Q9GZT9 1/20 0.37
KDM1A O60341 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30624087 0.89 ESR2 (0.44) ESR2NR1H2MAPTGPR119
SCHEMBL30624351 0.88 ESR2 (0.43) ESR2NR1H2MAPK1MAPTGPR119
SCHEMBL30624349 0.87 ESR2 (0.46) ESR2NR1H2MAPK1MKNK1MAPT
SCHEMBL31413089 0.87 ESR2 (0.44) ESR2NR1H2MAPK1MKNK1MAPT
SCHEMBL30474097 0.87 ESR2 (0.44) ESR2NR1H2MAPK1MKNK1MAPT
SCHEMBL30474260 0.86 ESR2 (0.44) ESR2NR1H2MAPK1MKNK1MAPT
SCHEMBL30474233 0.84 ESR2 (0.45) ESR2NR1H2MAPK1MKNK1MAPT
SCHEMBL31413147 0.84 ESR2 (0.45) ESR2NR1H2MAPK1MKNK1MAPT
SCHEMBL31413131 0.81 ESR2 (0.42) ESR2NR1H2MAPK1MKNK1MAPT
SCHEMBL30474258 0.81 ESR2 (0.42) ESR2NR1H2MAPK1MKNK1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250109148-A1 HETEROCYCLIC GLP-1 AGONISTS SHANGHAI SHOUTI BIOTECHNOLOGY CO., LTD. (CN) 2025-04-03 US disclosed
CN-119343339-A Heterocyclic GLP-1 agonists 加舒布鲁姆生物公司 2025-01-21 CN disclosed
EP-4469444-A1 HETEROCYCLIC GLP-1 AGONISTS Gasherbrum Bio, Inc. (US) 2024-12-04 EP disclosed
WO-2023138684-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO , INC. (US) 2023-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250109148-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR ESR2 447/4885NR1H2 456/4885MAPK1 763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.